You are here: Industry Insights > myeloma

News List

AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic biospace
March 22, 2018
AbbVie (NYSE: ABBV), today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage MM, the second most common blood cancer.1
GSK's experimental multiple myeloma scores Breakthrough designation with FDA pharmafile
November 06, 2017
GlaxoSmithKline is celebrating the FDA's decision to grant its experimental therapy GSK2857916 a breakthrough therapy designated as monotherapy in patients with multiple myeloma
Myeloma UK trial to test novel myeloma treatment approach pharmatimes
October 12, 2017
Myeloma UK has launched a nationwide trial aiming to assess the effectiveness of a novel treatment combination that includes Darzalex for patients with genetically-defined high-risk myeloma.
SMC approves Amgen’s carfilzomib for multiple myeloma treatment pharmaceutical-technology
August 10, 2017
The Scottish Medicines Consortium (SMC) has approved the routine use of Amgen’s carfilzomib (Kyprolis), in combination with dexamethasone, for the treatment of multiple myeloma across National Health Service (NHS) Scotland.
Revlimid boosts survival in myeloma patients post-transplant pharmatimes
July 31, 2017
a significant overall survival (OS) benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation
NICE set to reject Janssen’s Darzalex for multiple myeloma pharmatimes
March 20, 2017
Janssen said it is extremely concerned that the National Institute for Health and Care Excellence (NICE) has not ...
Myeloma UK launches ‘world first’ immunotherapy trial pharmatimes
March 20, 2017
Myeloma UK has launched a ground-breaking immunotherapy trial which aims to modulate the immune system to target myeloma.
Janssen and Bristol-Myers Squibb to Evaluate DARZALEX® in Combination with OPDIVO® americanpharmaceuticalreview
January 06, 2017
Janssen Biotech has entered a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the combination of the first CD38-directed cytolytic antibody daratumumab (DARZALEX®) and checkpoint inhibitor nivolumab (OPDIVO®) in Phase 1b/Phase 2

Previous page 1 2 3 4 Next page